Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765259 | 0.92 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL7160992 | 0.91 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KMT2AMAPTPOLB | |
| SCHEMBL6764637 | 0.89 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL6771746 | 0.89 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2KMT2AMAPTNPSR1 | |
| SCHEMBL6766824 | 0.88 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL8905502 | 0.85 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL9213271 | 0.83 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL8906891 | 0.83 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2KMT2AMAPTLMNA | |
| SCHEMBL8906443 | 0.82 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2KMT2ALMNAPOLB | |
| SCHEMBL8906884 | 0.82 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774133-B2 | Substituted spiroheterocyclic 1H-3-aryl-pyrrolidine-2,4-dione derivatives, processes for their preparation, and their use as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2004-08-10 | — | — | US | disclosed |
| US-20040009999-A1 | Substituted spiroheterocyclic 1H-3-aryl-pyrrolidine-2,4-dione derivatives, processes for their preparation, and their use as pesticides | FISCHER REINER (DE) | 2004-01-15 | — | — | US | disclosed |
| US-5981567-A | ARTHROPODICIDAL OR NEMATICIDAL COMPOSITION | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009999-A1 | Substituted spiroheterocyclic 1H-3-aryl-pyrrolidine-2,4-dione derivatives, processes for their preparation, and their use as pesticides | DDT, HPD, CAT | ALDH1A1 382/4885SMN1; SMN2 3044/4885KMT2A 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.